Bayer Aktiengesellschaft remains deeply undervalued despite ongoing operational and litigation headwinds, supporting a bullish stance. Q3/25 results were weak, but technicals and intrinsic value ...

Seven years ago, two events set forth a domino effect culminating in Bayer leaders having a potential “tough decision” of whether or not the company will continue to manufacture its legacy herbicide ...

Heading into the second half of their 2025 financial year, Bayer leaders echo positive comments surrounding the company’s crop science division. What has them bullish? First, Bayer is optimistic the ...

Managing diabetes already brings stress from medications and long-term health risks. Regular glucose checks only add to the weight. Most people test with finger pricks or wear a patch that needs a ...

EU leaders will loan 90 billion euros to Ukraine, but fail to agree to use frozen Russian assets European Union leaders decided to borrow cash to loan $105 billion to Ukraine to fund its defence ...

Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...

Alexandria Nyembwe is a registered nurse and health writer. She has worked in street medicine serving populations experiencing homelessness in Skid Row Los Angeles as well as in cardiovascular care in ...

Bayer shares are still down more than 60% since the company completed its purchase of Monsanto — primarily a manufacturer of seeds and herbicides — in June 2018. As part of the acquisition, Bayer also ...